Drug interactions
Buprenorphine subdermal implant + Dexamethasone-tobramycin
Severity: Moderate
Buprenorphine subdermal implant and Dexamethasone-tobramycin: moderate interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
CYP3A4 induction by dexamethasone may reduce buprenorphine concentrations and could cause withdrawal symptoms or loss of efficacy. The implant dose cannot be adjusted, which limits flexibility. With ophthalmic use, induction is unlikely to be significant.
What this interaction means in plain words
Buprenorphine subdermal implant and Dexamethasone-tobramycin can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken.
Why it happens
Dexamethasone induces CYP3A4, increasing buprenorphine metabolism.
What to do
Monitor for withdrawal symptoms if prolonged systemic dexamethasone is started. If symptoms persist, consider switching to a buprenorphine form that allows dose adjustment.
What to ask your pharmacist
- Should I take them at different times of day?
- Does the dose of either medicine need to change?
- Is there anything I should avoid, such as alcohol or certain foods, while on both?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Buprenorphine subdermal implant and Dexamethasone-tobramycin, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 7 days on the web. No card needed.
Other interactions of Dexamethasone-tobramycin
Frequently asked questions
Can I take Buprenorphine subdermal implant with Dexamethasone-tobramycin?
MediHelp rates the interaction as moderate. Buprenorphine subdermal implant and Dexamethasone-tobramycin can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken. CYP3A4 induction by dexamethasone may reduce buprenorphine concentrations and could cause withdrawal symptoms or loss of efficacy. The implant dose cannot be adjusted, which limits flexibility. With ophthalmic use, induction is unlikely to be significant.
How serious is the interaction between Buprenorphine subdermal implant and Dexamethasone-tobramycin?
MediHelp rates it moderate, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Monitor for withdrawal symptoms if prolonged systemic dexamethasone is started. If symptoms persist, consider switching to a buprenorphine form that allows dose adjustment.
What other medicines interact with Dexamethasone-tobramycin?
MediHelp also lists interactions of Dexamethasone-tobramycin with, for example, Capreomycin, Carboplatin, Ciprofloxacin. The full list is on the Dexamethasone-tobramycin page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
